Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Discovery of a potent and dissociated non-steroidal glucocorticoid receptor agonist containing an alkyl carbinol pharmacophore.

Razavi H, Riether D, Harcken C, Bentzien J, Dinallo RM, Souza D, Nelson RM, Kukulka A, Fadra-Khan TN, Pack EJ Jr, Zuvela-Jelaska L, Pelletier J, Panzenbeck M, Torcellini CA, Proudfoot JR, Nabozny GH, Thomson DS.

Bioorg Med Chem Lett. 2014 Apr 15;24(8):1934-40. doi: 10.1016/j.bmcl.2014.03.005. Epub 2014 Mar 12.

PMID:
24656565
2.

G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanism.

Fryer RM, Ng KJ, Nodop Mazurek SG, Patnaude L, Skow DJ, Muthukumarana A, Gilpin KE, Dinallo RM, Kuzmich D, Lord J, Sanyal S, Yu H, Harcken C, Cerny MA, Hickey ER, Modis LK.

J Pharmacol Exp Ther. 2014 Mar;348(3):421-31. doi: 10.1124/jpet.113.210005. Epub 2014 Jan 7. Erratum in: J Pharmacol Exp Ther. 2014 Apr;349(1):174. Cerny, Matthew C [corrected to Cerny, Matthew A]. J Pharmacol Exp Ther. 2014 Mar;348(3):492.

PMID:
24399854
3.

The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.

Fryer RM, Muthukumarana A, Harrison PC, Nodop Mazurek S, Chen RR, Harrington KE, Dinallo RM, Horan JC, Patnaude L, Modis LK, Reinhart GA.

PLoS One. 2012;7(12):e52985. doi: 10.1371/journal.pone.0052985. Epub 2012 Dec 28.

4.

Strategic integration of in vivo cardiovascular models during lead optimization: predictive value of 4 models independent of species, route of administration, and influence of anesthesia.

Fryer RM, Harrison PC, Muthukumarana A, Nodop Mazurek SG, Ng KJ, Chen RR, Harrington KE, Dinallo RM, Chi L, Reinhart GA.

J Cardiovasc Pharmacol. 2012 Apr;59(4):369-76. doi: 10.1097/FJC.0b013e31824485dd.

PMID:
22179024
5.

Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitors.

Fryer RM, Muthukumarana A, Chen RR, Smith JD, Mazurek SN, Harrington KE, Dinallo RM, Burke J, DiCapua FM, Guo X, Kirrane TM, Snow RJ, Zhang Y, Soleymanzadeh F, Madwed JB, Kashem MA, Kugler SZ, O'Neill MM, Harrison PC, Reinhart GA, Boyer SJ.

J Pharmacol Exp Ther. 2012 Mar;340(3):492-500. doi: 10.1124/jpet.111.189365. Epub 2011 Nov 29.

PMID:
22128344
6.

Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees.

Riska PS, Joseph DP, Dinallo RM, Davidson WC, Keirns JJ, Hattox SE.

Drug Metab Dispos. 1999 Dec;27(12):1434-47.

PMID:
10570025
7.

BIRM 270: a novel inhibitor of arachidonate release that blocks leukotriene B4 and platelet-activating factor biosynthesis in human neutrophils.

Farina PR, Graham AG, Hoffman AF, Watrous JM, Borgeat P, Nadeau M, Hansen G, Dinallo RM, Adams J, Miao CK, et al.

J Pharmacol Exp Ther. 1994 Dec;271(3):1418-26.

PMID:
7996454
8.

The characterization of synthetic by-products by B/E linked scanning and high-resolution thermospray mass spectrometry.

Dinallo RM, Davidson WC, Hansen GE.

Biol Mass Spectrom. 1991 May;20(5):268-74.

PMID:
1715757

Supplemental Content

Loading ...
Support Center